In a Friday interview with CNBC’s Jim Cramer, Recursion Pharmaceuticals CEO Chris Gibson explained how his company uses new AI technology to develop…
In a Friday interview with CNBC's Jim Cramer, Recursion Pharmaceuticals CEO Chris Gibson discussed how his company is using artificial intelligence and machine learning to create new drugs.CEO Chris Gibson discussed how his company is using artificial intelligence and machine learning to make the process of developing drugs faster and less expensive.last summer.
"I think with clinical trials, there's still going to be a few years to get through the clinical trial space," Gibson said."But, to find the drug and get it into the clinic, I think we can shorten that from five or six years and hundreds of millions of dollars into, perhaps, one or two years and just $10 or $20 million."
Recursion is currently developing a new drug to treat cerebral cavernous malformation, a neurovascular disease that Gibson said is not widely known, but affects six times as many people in the U.S. than cystic fibrosis. Before Recursion's AI-focused approach, no one had any idea of how to make a drug for this disease, he said. The new treatment is almost done with its phase two trials.
Gibson said he thinks this kind of approach to drug development, using new technology to map biology, will be common in the biopharma industry in five or ten years. "Think of it as, like, Google Street View driving around taking pictures of everything," he said."We have microscopes taking tens of millions of pictures of cells every week, and we're using a lot of the same AI algorithms to turn those images into mathematical representations of biology that we think could unlock some really exciting secrets."Feeling out of the loop? We'll catch you up on the Chicago news you need to know.
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Recursion Pharmaceuticals CEO explains how AI could make drug development faster and less costlyIn a Friday interview with CNBC's Jim Cramer, Recursion Pharmaceuticals CEO Chris Gibson explained how his company uses new AI technology to develop drugs.
Read more »
CEO Talks: L.L. Bean CEO Talks Importance of Summer, U.S. Market and Tote BagsL.L. Bean's fiscal 2023 sales were $1.7 million, a slight decline compared to $1.8 million for the previous fiscal year.
Read more »
Flos CEO Roberta Silva Steps DownFlos CEO Roberta Silva is replaced by Design Holding CEO Daniel Lalonde in the interim.
Read more »
Pharmaceuticals’ bay impact an ‘open-ended question’It’s unclear just how many unused medications and other pharmaceutical waste is getting into local waters and impacting the ecosystem
Read more »
Sustainable synthesis method reveals N-hydroxy modifications for pharmaceuticalsRecently published research results enable preparative access to novel substances that carry a modification of a structural motif frequently found in pharmaceuticals.
Read more »
Jim Cramer shares his thoughts on Nike, Vertex Pharmaceuticals, CarMax, Airbnb, Visa and MastercardDuring the CNBC Investing Club's Morning Meeting, Jim Cramer weighed in on the stock moves in Nike, Vertex Pharma and more.
Read more »